Adult diagnosis of Cockayne syndrome

Neurology® 2020;95:802. doi:10.1212/WNL.0000000000008878

In the Video NeuroImage article “Adult diagnosis of Cockayne syndrome” by Cocco et al.,¹ the figure title should be “Axial T2- and T1-weighted MRI and axial CT scan” and its legend should read “Axial T2-weighted (A–B) and T1-weighted (C) MRI show white matter abnormalities and brain calcifications. Axial CT scan (D–F) demonstrates calcifications in the cortical sulci, basal ganglia, and cerebellum.” The publisher regrets the errors.

Reference

1. Cocco A, Calandrella D, Carecchio M, Garavaglia B, Albanese A. Adult diagnosis of Cockayne syndrome. *Neurology* 2019;93:854–855.

Determination of death by neurologic criteria around the world

Neurology® 2020;95:802. doi:10.1212/WNL.0000000000010541

In the article “Determination of death by neurologic criteria around the world” by A. Lewis et al.,¹ first published online June 23, 2020, the following names included in the “Acknowledgment” section should appear as: Abualia, Mohammad (Jordan); Abulhasan, Yasser (Kuwait); and Mejia-Mantilla, Jorge (Colombia). The names appear correctly in the July 21, 2020, issue. The authors regret these errors.

Reference

1. Lewis A, Bakkar A, Krieger-Benson E, et al. Determination of death by neurologic criteria around the world. *Neurology* 2020;95:e299–e309.

Frequency and risk factors of antibody-induced secondary failure of botulinum neurotoxin therapy

Neurology® 2020;95:802. doi:10.1212/WNL.0000000000010543

In the short form of the article “Frequency and risk factors of antibody-induced secondary failure of botulinum neurotoxin therapy” by U. Walter et al.,¹ the final sentence under sub-heading “Main results and the role of chance” should read “NAB-induced complete STF did not occur in patients treated exclusively with incobotulinumtoxinA.” The editors and authors regret the error.

Reference

1. Walter U, Mühlenhoff C, Benecke R, et al. Frequency and risk factors of antibody-induced secondary failure of botulinum neurotoxin therapy. *Neurology* 2020;94:e2109–e2120.

Neurology®

Frequency and risk factors of antibody-induced secondary failure of botulinum neurotoxin therapy

Neurology 2020;95;802 Published Online before print July 30, 2020

DOI 10.1212/WNL.00000000000010543

This information is current as of July 30, 2020

Updated Information & Services

including high resolution figures, can be found at:
<http://n.neurology.org/content/95/17/802.3.full>

References

This article cites 1 articles, 1 of which you can access for free at:
<http://n.neurology.org/content/95/17/802.3.full#ref-list-1>

Permissions & Licensing

Information about reproducing this article in parts (figures, tables) or in its entirety can be found online at:
http://www.neurology.org/about/about_the_journal#permissions

Reprints

Information about ordering reprints can be found online:
<http://n.neurology.org/subscribers/advertise>

Neurology® is the official journal of the American Academy of Neurology. Published continuously since 1951, it is now a weekly with 48 issues per year. Copyright © 2020 American Academy of Neurology. All rights reserved. Print ISSN: 0028-3878. Online ISSN: 1526-632X.